@phdthesis{Berberich2020,
  author    = {Berberich, Sara},
  title     = {Adh{\"a}renz bei oraler Capecitabin-Therapie : Zusammenh{\"a}nge mit Progredienzangst},
  doi       = {10.25972/OPUS-20980},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-209800},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2020},
  abstract  = {Krebserkrankungen stellen eine lebensver{\"a}ndernde und potentiell letale Diagnose dar. Orale Zytostatika stellen eine vielversprechende Therapiem{\"o}glichkeit dar. Ein h{\"a}ufig eingesetztes orales Zytostatikum ist Capecitabin. Durch den Einsatz von oralen Chemotherapeutika ergeben sich viele Vorteile. Grundlegende Voraussetzung f{\"u}r den Einsatz der Tablettenform ist allerdings eine {\"a}quivalente Wirksamkeit. Diese h{\"a}ngt entscheidend von ausreichender Adh{\"a}renz der Patienten ab. In dieser Studie konnte bei der Auswertung des MARS-D gezeigt werden, dass 25 \% der Studienteilnehmer nicht ausreichend adh{\"a}rent waren. H{\"a}ufigster Grund f{\"u}r Nicht-Adh{\"a}renz war das Vergessen der Medikamenteneinnahme. Ein weiteres, wichtiges Ergebnis dieser Pilotstudie war, dass die Probanden ihre Adh{\"a}renz subjektiv deutlich h{\"o}her einsch{\"a}tzten (M im VAS 97,72) als sich bei der Auswertung des MARS-D best{\"a}tigen ließ. Die Erkennung und Behandlung psychischer Beeintr{\"a}chtigungen und Erkrankungen ist bei der Betreuung von Krebspatienten entscheidend. Fear of progression (FOP) ist die am h{\"a}ufigsten ge{\"a}ußerte Angst von Krebspatienten. Diese Studie konnte die Bedeutung von FOP deutlich zeigen: bei 38 \% der Probanden konnte eine dysfunktionale Form der FOP nachgewiesen werden. Nur vier Studienteilnehmer nutzten allerdings psychosomatische/psychiatrische Unterst{\"u}tzungm{\"o}glichkeiten. Die Single-Item Analyse des PA-F-KF zeigten sich {\"A}ngste im Vordergrund stehend, welche den Bereich Familie betrafen. {\"U}berraschenderweise ließ sich zwischen der h{\"a}ufigsten Nebenwirkung Hand-Fuß-Syndrom und FOP kein signifikanter Zusammenhang nachweisen. Dagegen konnten stark signifikante Zusammenh{\"a}nge zwischen dem Auftreten von Diarrhoen, {\"U}belkeit, Ersch{\"o}pfung und dysfunktionaler FOP gezeigt werden.},
  subject      = {Zukunftsangst},
  language  = {de}
}
@article{OregliaSbieraFassnachtetal.2020,
  author    = {Oreglia, Maurine and Sbiera, Silviu and Fassnacht, Martin and Guyon, Laurent and Denis, Josiane and Cristante, Justine and Chabre, Olivier and Cherradi, Nadia},
  title     = {Early postoperative circulating miR-483-5p is a prognosis marker for adrenocortical cancer},
  series = {Cancers},
  volume    = {12},
  journal   = {Cancers},
  number    = {3},
  issn      = {2072-6694},
  doi       = {10.3390/cancers12030724},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-203227},
  year      = {2020},
  abstract  = {We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (p = 0.002). Receiver operating characteristic analysis showed that a value of 752,898 copies/mL distinguished R < 3yrs from NR3yrs with 61.5\% sensitivity (CI 31.6-86.1) and 100\% specificity (CI 71.5-100) with an area under the curve of 0.853. Patients with a value below this threshold had a significantly longer recurrence-free and overall survival. In multivariate analysis, miR-483-5p provided the single best prognostic value for recurrence-free survival (RFS) (hazard ratio (HR) for recurrence 5.98, p < 0.011) but not for overall survival. Our study suggests that serum miR-483-5p is a potent early post-operative biomarker for ACC prognosis that might be a better predictor of RFS than currently used markers.},
  language  = {en}
}
@article{KesslerFeldheimSchmittetal.2020,
  author    = {Kessler, Almuth F. and Feldheim, Jonas and Schmitt, Dominik and Feldheim, Julia J. and Monoranu, Camelia M. and Ernestus, Ralf-Ingo and L{\"o}hr, Mario and Hagemann, Carsten},
  title     = {Monopolar Spindle 1 Kinase (MPS1/TTK) mRNA Expression is Associated with Earlier Development of Clinical Symptoms, Tumor Aggressiveness and Survival of Glioma Patients},
  series = {Biomedicines},
  volume    = {8},
  journal   = {Biomedicines},
  number    = {7},
  doi       = {10.3390/biomedicines8070192},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236105},
  year      = {2020},
  abstract  = {Inhibition of the protein kinase MPS1, a mitotic spindle-checkpoint regulator, reinforces the effects of multiple therapies against glioblastoma multiforme (GBM) in experimental settings. We analyzed MPS1 mRNA-expression in gliomas WHO grade II, III and in clinical subgroups of GBM. Data were obtained by qPCR analysis of tumor and healthy brain specimens and correlated with the patients' clinical data. MPS1 was overexpressed in all gliomas on an mRNA level (ANOVA, p < 0.01) and correlated with tumor aggressiveness. We explain previously published conflicting results on survival: high MPS1 was associated with poorer long term survival when all gliomas were analyzed combined in one group (Cox regression: t < 24 months, p = 0.009, Hazard ratio: 8.0, 95\% CI: 1.7-38.4), with poorer survival solely in low-grade gliomas (LogRank: p = 0.02, Cox regression: p = 0.06, Hazard-Ratio: 8.0, 95\% CI: 0.9-66.7), but not in GBM (LogRank: p > 0.05). This might be due to their lower tumor volume at the therapy start. GBM patients with high MPS1 mRNA-expression developed clinical symptoms at an earlier stage. This, however, did not benefit their overall survival, most likely due to the more aggressive tumor growth. Since MPS1 mRNA-expression in gliomas was enhanced with increasing tumor aggressiveness, patients with the worst outcome might benefit best from a treatment directed against MPS1.},
  language  = {en}
}
@article{FeldheimKesslerSchmittetal.2020,
  author    = {Feldheim, Jonas and Kessler, Almuth F. and Schmitt, Dominik and Salvador, Ellaine and Monoranu, Camelia M. and Feldheim, Julia J. and Ernestus, Ralf-Ingo and L{\"o}hr, Mario and Hagemann, Carsten},
  title     = {Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma — A New Disease Biomarker?},
  series = {Cancers},
  volume    = {12},
  journal   = {Cancers},
  number    = {5},
  issn      = {2072-6694},
  doi       = {10.3390/cancers12051085},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-203648},
  year      = {2020},
  abstract  = {Despite its significant overexpression in several malignant neoplasms, the expression of RPS27 in the central nervous system (CNS) is widely unknown. We identified the cell types expressing RPS27 in the CNS under normal and disease conditions. We acquired specimens of healthy brain (NB), adult pilocytic astrocytoma (PA) World Health Organization (WHO) grade I, anaplastic PA WHO grade III, gliomas WHO grade II/III with or without isocitrate dehydrogenase (IDH) mutation, and glioblastoma multiforme (GBM). RPS27 protein expression was examined by immunohistochemistry and double-fluorescence staining and its mRNA expression quantified by RT-PCR. Patients' clinical and tumor characteristics were collected retrospectively. RPS27 protein was specifically expressed in tumor cells and neurons, but not in healthy astrocytes. In tumor tissue, most macrophages were positive, while this was rarely the case in inflamed tissue. Compared to NB, RPS27 mRNA was in mean 6.2- and 8.8-fold enhanced in gliomas WHO grade II/III with (p < 0.01) and without IDH mutation (p = 0.01), respectively. GBM displayed a 4.6-fold increased mean expression (p = 0.02). Although RPS27 expression levels did not affect the patients' survival, their association with tumor cells and tumor-associated macrophages provides a rationale for a future investigation of a potential function during gliomagenesis and tumor immune response.},
  language  = {en}
}